CN1314454C - Duplication method of chmice acute hyperuricemia model - Google Patents
Duplication method of chmice acute hyperuricemia model Download PDFInfo
- Publication number
- CN1314454C CN1314454C CNB2005100403959A CN200510040395A CN1314454C CN 1314454 C CN1314454 C CN 1314454C CN B2005100403959 A CNB2005100403959 A CN B2005100403959A CN 200510040395 A CN200510040395 A CN 200510040395A CN 1314454 C CN1314454 C CN 1314454C
- Authority
- CN
- China
- Prior art keywords
- model
- group
- uric acid
- hyperuricemia
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a duplication method for the acute hyperuricemia model of a mouse. In the method, a healthy female or male mouse belonging to the species of Kunming or ICR and having the weight of 16 to 35 g is selected and is fasting or not fasting, and purine, namely 100 to 1500 mg/kg of hypoxanthine or xanthine and 10 to 1500 mg/kg of uric acid inhibitor OA or allantoxanamide, is simultaneously injected in the rat in the mode of stomach filling, hypodermic injection or intraperitoneal injection at the room temperature; the results of an experiment indicate that the optimal dosage of the purine is 500 mg/kg, and the optimal dosage of the uric acid inhibitors is 50 mg/kg. The experiment proves that a stable hyperuricemia model of the mouse can be obtained by matching the uricase inhibitors with the purine for one hour, the hyperuricemia level of the mouse is obviously enhanced and is higher than the saturated concentration of 417 mu mol/L<-1> of crystals generated by uric acids, and the level can be kept for more than seven hours.
Description
One, technical field
The present invention relates to the clone method of animal model, specifically relate to the clone method of chmice acute hyperuricemia model.
Two, background technology
Gout be purine metabolic disturbance or (with) urate excretion reduces caused one group of different substantiality disease.Be principal character clinically with the hyperuricemia, hyperuricemia is the biochemical basis of gout, and gout is inevitable with hyperuricemia.In essence, there is no strict boundary between hyperuricemia and the gout.The pathogenesis and the Drug therapy thereof of Recent study gout become one of focus of medical circle, still lack the mature animal model of relevant gout at present both at home and abroad, and making up the hyperuricemia animal disease model then is the prerequisite of gout research.Also have a lot of incomplete places in the existing model, thereby brought great inconvenience for the research of gout.Below some representational mice hyperuricemia animal models are done and briefly introduced.
1. Kunming mouse is male, body weight 20 ± 2g.Use xanthine 600mg/kg and ethambutol 250mg/kg, hypoxanthine 600mg/kg and nicotinic acid 100mg/kg, continuous 5 days of ig administration causes the mice hyperuricemia model.(Jin Shenrui, Zheng Jun, Liu Shaotang. experimental animal model research-mice hyperuricemia model pre-test [J]. Chengdu University of Traditional Chinese Medicine's journal, 1999,22 (1): 49～50.)
2. Kunming mouse, male and female all can, body weight 20 ± 2g, hypoxanthine 1000mg/kg, the ip injection causes the mice hyperuricemia model.(Tang Can, Yang Kui. hyperuricemia animal model pre-test [J]. new Chinese medicine and clinical pharmacology, 2000,11 (5): 292～294.)
3. Kunming mouse, male and female half and half, body weight 22 ± 2g.Use uric acid 150～1000mg/kg, the ip injection causes the mice hyperuricemia model.(Chen Guangliang, Sun Xiuxia, Wang Qinmao etc. the research of mice hyperuricemia model [J]. Chinese Pharmacological circular, 2001,17 (3): 350.)
4. Kunming mouse is male, body weight 28 ± 2g.Use uricase inhibitor oxonic acid 300mg/kg, the ip injection causes the mice hyperuricemia model.(Iris HH，Scoville JP，Davide J，etal.Substituted cyclic im ides as potencial anti-gout agents[J].LifeSciences，1990，46(26)：1923～1927.)
5. Kunming mouse, male and female half and half.Use yeast extract to irritate stomach with 15～30g/kg/d, continuous irrigation stomach 1～2wk copies the mice hyperuricemia model.(Chen Guangliang, Zhang Qinglin, Ma Xiaoqin etc. yeast causes mice hyperuricemia model [J]. Chinese Pharmacological circular, 2003,19 (4): 467.)
6. at first destroy the mice urate oxidase gene by adopting, the reuse method of gene recombination obtains the enzymoprivic mutant mice of uric acid, thereby causes the hyperuricemia model mice.(Wu-X.Hyperuricemia and uratenephropahty in urate oxidase-deficient mice[J].Proc Natl Acad Sci U.S.A，1994，91(2)：742.)
Uric acid can not be utilized by human body or decompose in vivo, in the environment of normal person's body fluid pH7.4, be the uric acid na form, dissolubility 417 μ mol/L (7mg/dl) (the Yin Weihe River. hyperuricemia and gout [J]. the doctor studies magazine, 1998,21 (11): 573), just can be deposited in the tissue so uric acid concentration must be higher than this value.Employing gives heavy dose of purine substance, suppresses the medicine of urate excretion simultaneously, promptly by increasing the incoming road of uric acid in the body, and suppresses uric acid and excretes, and blood uric acid content is increased, and causes the hyperuricemia model of mice.This kind model approaches the mechanism of production of human hyperuricemia and gout, provides feasible research method for studying gout and hyperuricemia and assessing medicine for treatment.This model must be in conjunction with the drug use of purine substance and inhibition urate excretion, if simple heavy dose gives the mice purine substance continuously, blood uric acid was a height with 5 days, and 10 days blood uric acids descend on the contrary.And the formed metabolic arthritis level of this model is far below the concentration of crystallization deposition.A direct injection hypoxanthine also can duplicate the hyperuricemia animal model, and animal subject reaches 631.5 ± 72.99 μ mol/L (being equivalent to 10.5mg/dl) in 1h blood uric acid concentration, and 2h promptly quickly falls to below the saturated concentration, the weak point of holding time.And the lumbar injection uric acid also only has the dosage of 1000mg/kg at 40min the mice uric acid level is reached about 450 μ mol/L (being equivalent to 7.5mg/dl), and all the other dosage all can not reach the sedimentary saturated concentration of uric acid at the uric acid level of each point, and it is very short to hold time.This is owing to have uricase in the mammalian body, uric acid in the body further can be decomposed, excrete, thus select for use the uricase inhibitor oxonic acid to suppress the uricase activity, thus uricolysis suppressed.But the oxonic acid utmost point improves the mice serum uric acid level significantly, and the hematuria acid number can reach 6.72 ± 0.08mg/dl, causes the mice hyperuricemia model, and its serum metabolic arthritis level can be kept 5h.(analogy will peak, Yang Cheng, Chou Xi. daphnin is to the influence [J] of hyperuricemia mice. China Medicine University's journal, 2002,33 (2): 142～145), easy, the good reproducibility of this method sensitivity is generally estimated the anti-hyperuricemia and the gout effect of medicine in the world with this.(James J, Carroll, Holly Coburn, et al.Asimplified alkaline phosphotungstate assay for uric acid inserum[J] .Clinical Chemistry, 1997,17 (3): 158～160), but the metabolic arthritis level due to the oxonic acid does not surpass 7mg/dl as yet, though can keep 5h, but not reach the level of urate deposition, therefore can't form gouty arthritis.Use the gene mutation method to duplicate animal model, this method can not be survived more than 4 weeks mutant mices more than half, and document do not have final conclusion to this method yet, more sees the difficulty of this model.
Three, summary of the invention
1. goal of the invention
The object of the present invention is to provide a kind of clone method that meets clinical chmice acute hyperuricemia model more, and make the metabolic arthritis level of this mouse model be elevated to saturated concentration and can keep time enough.
2. technical scheme
2.1 animal: mice.Kind: Kunming kind, ICR.Body weight: more than the 16g.
2.2 modeling medicine
Title: purine class: hypoxanthine, xanthine.Uricase inhibitor: Oxonic acid, potassium salt (OA), allantoxanamide.
Route of administration: irritate stomach, subcutaneous injection, lumbar injection.
Dosage: purine class: 100～1500mgkg
-1
Uricase inhibitor: 10～1500mgkg
-1
Solvent: normal saline, liquid paraffin, CMC-Na, oil, soluble starch.
Preparation requires: the preparation of suspensoid is must concentration even, will shake up during use.
2.3 the clone method of chmice acute hyperuricemia model, this method is to choose Kunming kind, ICR healthy mice, female or male, body weight 18～35g, fasting, non-fasting all can, under room temperature, give purine class and uricase inhibitor with irritating stomach, subcutaneous injection or lumbar injection mode simultaneously to mice, but ad lib, drinking-water after the modeling.
Above-mentioned purine class is hypoxanthine, xanthine, and its consumption is 100～1500mgkg
-1
Above-mentioned uricase inhibitor is OA, allantoxanamide, and its consumption is 10～1500mgkg
-1
The optimum amount of above-mentioned purine class is 500mgkg
-1, the optimum amount of uricase inhibitor is 50mgkg
-1
3. beneficial effect
In this experiment, we use uricase inhibitor to cooperate the purine class, and 1h can obtain stable mice hyperuricemia model.The serum uric acid level of animal can improve significantly, is higher than uric acid and produces crystalline saturated concentration 417 μ molL
-1, this level can be kept more than the 7h.The mechanism of this and hyperuricemia is coincide, increase the interior purine class of animal body to increase the raw material that generates uric acid, use the decomposition of uricase inhibitor inhibition simultaneously to uric acid, reduce the outlet of uric acid with this, both are collaborative, thereby obviously improve serum uric acid level, and the metabolic arthritis level is held time and is obviously prolonged.As seen, purine class and uricase inhibitor are used, and are the desirable combination that copies hyperuricemia model.Provide valuable reference for duplicating the persistence hyperuricemia model and then duplicating the gout model.
Four, the specific embodiment
The clone method of embodiment 1. chmice acute hyperuricemia models, its method is as follows:
Select Kunming mouse for use, male, 20g ± 2g at room temperature, with irritating the stomach mode, irritates hypoxanthine 1000mgkg
-1, use the lumbar injection mode, injection OA 100mgkg
-1
The clone method of embodiment 2. chmice acute hyperuricemia models, its method is as follows:
Select Kunming mouse for use, male, 20g ± 2g at room temperature, with irritating the stomach mode, irritates hypoxanthine 1000mgkg
-1, use the lumbar injection mode, injection OA 600mgkg
-1
The clone method of embodiment 3. chmice acute hyperuricemia models, its method is as follows:
Select Kunming mouse for use, male, 20g ± 2g at room temperature, with irritating the stomach mode, irritates hypoxanthine 1000mgkg
-1, use the subcutaneous injection mode, injection OA 100mgkg
-1
The clone method of embodiment 4. chmice acute hyperuricemia models, its method is as follows:
Select Kunming mouse for use, male, 20g ± 2g at room temperature, with irritating the stomach mode, irritates hypoxanthine 1000mgkg
-1, use the subcutaneous injection mode, injection OA 600mgkg
-1
The clone method of embodiment 5. chmice acute hyperuricemia models, its method is as follows:
Choose kunming mice, male, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 1000mgkg
-1Use the subcutaneous injection mode, injection OA 1000mgkg
-1
The clone method of embodiment 6. chmice acute hyperuricemia models, its method is as follows:
Choose kunming mice, male, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 1000mgkg
-1Use the subcutaneous injection mode, injection OA 400mgkg
-1
The clone method of embodiment 7. chmice acute hyperuricemia models, its method is as follows:
Choose kunming mice, male, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 500mgkg
-1Use the subcutaneous injection mode, injection OA 400mgkg
-1
The clone method of embodiment 8. chmice acute hyperuricemia models, its method is as follows:
Choose kunming mice, male, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 500mgkg
-1Use the subcutaneous injection mode, injection OA 100mgkg
-1
The clone method of embodiment 9. chmice acute hyperuricemia models, its method is as follows:
Choose kunming mice, male, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 500mgkg
-1Use the subcutaneous injection mode, injection OA 50mgkg
-1
The clone method of embodiment 10. chmice acute hyperuricemia models, its method is as follows:
Choose kunming mice, male, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 250mgkg
-1Use the subcutaneous injection mode, injection OA 50mgkg
-1
The clone method of embodiment 11. chmice acute hyperuricemia models, its method is as follows:
Choose Kunming mouse, male and female half and half, 20g ± 2g at room temperature, uses the lumbar injection mode, injection hypoxanthine 500mgkg
-1Use the subcutaneous injection mode, injection OA 50mgkg
-1
The utilization of embodiment 12. chmice acute hyperuricemia models in antigout drug research.
1. experiment material
1.1 animal: Kunming mouse, male, 20g ± 2g.Experimental animal feeding credit number: SYXK (Soviet Union) 2002-0002 is provided by Nanjing University of Traditional Chinese Medicine's Experimental Animal Center.
1.2 medicine: Oxonic acid, potassium salt (OA), sigma-Aldrich company; Hypoxanthine (Hypoxanthine, HX), chemical plant, the northeast part of China, Tianjin; All use oil as solvent, add a little oil during preparation earlier, after putting into mortar and grinding well, remaining oil is being added.Add flavor four wonderful recipes (being called for short full side), 4g crude drug/ml; Add flavor four wonderful recipe effective part groups (being called for short A side): 4g crude drug/ml; Provide by Chemistry for Chinese Traditional Medicine teaching and research room of Nanjing University of Traditional Chinese Medicine.Allopurinol tablet: the 100mg/ sheet is made into the concentration of 2.75mg/ml, Yan'an Wanxiang Pharmaceutical Co., Ltd., Shanghai.The uric acid reagent box is Sysmex company product.
1.3 instrument: Hitachi's 7020 automatic clinical chemistry analyzers.
2. method and result
2.1 different approaches, various dose (OA) are divided into 5 groups to the influence of mice serum uric acid level at random with 40 mices, normal control group, model I group, model II group, model III group, model IV group, 8 every group.Model I group is irritated stomach HX 1000mgkg
-1+ lumbar injection OA 100mgkg
-1, model II group is irritated stomach HX 1000mgkg
-1+ lumbar injection OA 600mgkg
-1, model III group is irritated stomach HX 1000mgkg
-1+ subcutaneous injection OA100mgkg
-1, model IV group is irritated stomach HX 1000mgkg
-1+ subcutaneous injection OA 600mgkg
-1, get blood respectively at 2h, 5h after the modeling, centrifuging and taking serum is surveyed the hematuria acid number.The results are shown in Table 1.
Table 1 different approaches, various dose OA are to influence (X ± S) (n=8) of mice serum uric acid level
| Group | HX dosage/mgkg -1 | OA dosage/mgkg -1 | Hematuria acid number/μ molL -1 | |
| 2h | 5h | |||
| Matched group model I group model II group model III group model IV group | -- 1000 1000 1000 1000 | -- 100 600 100 600 | 169.8±58.6 157.0±2.8 224.2±63.4 115.5±46.6 319.5± 106.5** | 162.3±30.6 167.7±34.4 265.7±113.5 123.2±39.0 357.6±363.5 |
Compare * P＜0.05, * * P＜0.01 with matched group; Compare with model I group,
▲P＜0.05,
▲ ▲P＜0.01.
The result shows, 2h after modeling, and model IV group hematuria acid number and normal control group have significant difference (P＜0.01).Model I group, model II group, model III group and the equal zero difference of normal control group serum uric acid level.Explanation gives doses OA by the subcutaneous injection approach under the prerequisite that does not change hypoxanthine consumption and route of administration, the mice serum uric acid level that can raise, but it is shorter to hold time.
2.2 the influence that HX and OA share the mice serum uric acid level is divided into 8 groups at random with 64 mices, normal control group, model I group, model II group, model III group, model IV group, model V group, model VI group, model VII group, 6 every group.HX adopts lumbar injection, and OA adopts subcutaneous injection.Dosage sees Table 2.Get blood respectively at 1h, 3h after the modeling, centrifuging and taking serum is surveyed the hematuria acid number.The results are shown in Table 2.
Table 2 HX and OA share the influence of mice blood uric acid (X ± S) (n=6)
| Group | HX dosage/mgkg -1 | OA dosage/mgkg -1 | Hematuria acid number/μ molL -1 | |
| 1h | 3h | |||
| Control group model I group model II group model III group model IV group model V group model VI group model VII group | -- 1000 1000 1000 500 500 500 250 | -- -- 1000 400 400 100 50 50 | 156.3±46.1 535.0±384.0** 427.3±49.4** 827.7±228.1** 594.2±103.5** 892.8±308.5** 688.6±94.2** 361.2±246.7* | 141.9±55.2 220.3±69.9* 624.3±203.1**▲ ▲ 1034.6±355.3** ▲▲ 682.0±94.7**▲ ▲ 997.2±455.0**▲ ▲ 823.4±399.5**▲ ▲ 336.8±194.3** |
Compare * P＜0.05, * * P＜0.01 with matched group; Compare with model I group,
▲P＜0.05,
▲ ▲P＜0.01.
The result shows, after adopting various dose modeling 1h, 3h, each is organized serum uric acid level and all is higher than the normal control group, model VII group has certain difference (P＜0.05) at 1h, model I group 3h after modeling after the modeling with matched group, all the other each organize and all significant difference (P＜0.01) arranged with matched group at each point; Except model VII group, each group 3h after modeling all has significant difference (P＜0.01) with model I group.The above results shows: though only give HX the mice serum uric acid level that can raise, it is shorter to hold time, and serum uric acid level obviously reduces behind the administration 3h, therefore is unfavorable for carrying out the research of anti-antihyperuricemic disease drug.And if HX and OA are used, the serum uric acid level of the mice that then not only can raise can also be kept more than the 3h.From table 2, adopt HX250mgkg
-1With OA 50mgkg
-1The dosage group can obtain comparatively stable mice hyperuricemia model.But as it is constant to keep OA dosage, and HX dosage is doubled, and the mouse retention acid number is significantly improved, and reaches 600 μ molL
-1More than.Therefore, we think and adopt HX500mgkg
-1With OA 50mgkg
-1The dosage group be the optimal dose combination of duplicating stable chmice acute hyperuricemia model.
2.3 observe the uric acid resisting effect add the four wonderful recipe effective part groups of distinguish the flavor of mice is divided into 5 groups of blank groups, model group, positive group, full side group, A side's group etc. at random, 8 every group, gastric infusion respectively, blank is organized and model group gives the equal-volume normal saline.Continuous three days.1h after the administration in the 3rd day is except that the blank group, to each group mouse peritoneal injection HX5mg/10g (0.2ml/10g)+subcutaneous injection OA 0.5mg/10g (0.1ml/10g).Blank group abdominal cavity and the subcutaneous equal-volume oil that gives.1h, 3h after modeling get blood 0.3ml to mice, and be centrifugal, gets serum, surveys the hematuria acid number.The results are shown in Table 3.
Table 3 adds influence (X ± S) (n=8) of flavor four wonderful recipe effective part groups to the mice blood uric acid
| Group | Dosage/gkg -1 | Hematuria acid number/μ molL -1 | |
| 1h | 3h | ||
| The full side of the positive group of blank group model group group A side group | -- -- 0.055 120 120 | 130.4±15.82** 1781.1±499.32 10.6±2.19** 1478.7±312.04 1083.8±423.51** | 119.6±13.35** 1331.4±347.04 31.0±12.83** 822.3±415.91* 588.2±267.67** |
Compare * P＜0.05, * * P＜0.01 with model group.
The result shows that behind 1h, 3h after the modeling, the model group serum uric acid level is significantly higher than normal control group (P＜0.01), and modeling 1h uric acid level peaks, and the hematuria acid number still produces crystalline saturated concentration far above uric acid during 3h.The positive is organized and added flavor four wonderful recipe effective site groups all significant uric acid resisting effect (P＜0.01) at two test point places.Though prompting is after modeling, animal hematuria acid number can reach 1000 μ molL
-1More than, but the blood uric acid height of this model is not irreversible, from experimental result, be subjected to the reagent thing after, can find out obviously that medicine has the effect of uric acid resisting to animal pattern.Show the feasibility of this model in the pharmacological evaluation process.
In sum, select suitable modeling medicine, make appropriate dosage, administration time, administering mode, copy and more approach the formed mice hyperuricemia model of human purine metabolism obstacle, will make us deeply observe the influence that animal pattern kidney uric acid is discharged by the reagent thing, become possibility in the influence of articular cavity process, thereby provide necessary and animal model reliably for the research of the screening of anti-gout drugs and the mechanism of action to the effect link of purine metabolism and to urate deposition.
Claims (5)
1, a kind of clone method of chmice acute hyperuricemia model, it is characterized in that it is to choose Kunming kind or ICR healthy mice, female or male, body weight 16g-35g, fasting or non-fasting are under room temperature, adopt lumbar injection purine and subcutaneous injection uric acid enzyme inhibitor to unite use, but ad lib, drinking-water after the modeling, the blood uric acid of one hour animal is increased to 417-892 μ mol/L rapidly after the modeling, and the time of keeping more than saturated concentration is 3～5h.
2, clone method according to claim 1 is characterized in that described purine class is hypoxanthine, xanthine, and described uricase inhibitor is an oxonic acid potassium salt.
3, clone method according to claim 1 is characterized in that hypoxanthic consumption is 500～1000mgkg
-1, the consumption of oxonic acid potassium salt is 50～1000mgkg
-1
4, clone method according to claim 2 is characterized in that the solvent of described hypoxanthine and oxonic acid potassium salt is oil.
5, clone method according to claim 3 is characterized in that hypoxanthic consumption is 500mgkg
-1, the consumption of oxonic acid potassium salt is 50mgkg
-1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100403959A CN1314454C (en) | 2005-06-06 | 2005-06-06 | Duplication method of chmice acute hyperuricemia model |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100403959A CN1314454C (en) | 2005-06-06 | 2005-06-06 | Duplication method of chmice acute hyperuricemia model |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698907A CN1698907A (en) | 2005-11-23 |
| CN1314454C true CN1314454C (en) | 2007-05-09 |
Family
ID=35475259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100403959A Expired - Fee Related CN1314454C (en) | 2005-06-06 | 2005-06-06 | Duplication method of chmice acute hyperuricemia model |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314454C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6496107B2 (en) * | 2014-05-08 | 2019-04-03 | 株式会社フェニックスバイオ | Hyperuricemia model |
| CN110338139B (en) * | 2019-07-03 | 2021-10-26 | 安徽省立医院 | Construction method and application of gout animal model |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401380A (en) * | 2002-09-05 | 2003-03-12 | 南京大学 | Anti-gout composition and preparing process thereof |
-
2005
- 2005-06-06 CN CNB2005100403959A patent/CN1314454C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401380A (en) * | 2002-09-05 | 2003-03-12 | 南京大学 | Anti-gout composition and preparing process thereof |
Non-Patent Citations (5)
| Title |
|---|
| 小鼠高尿酸血症复合模型初探 张浩军等，北京中医药大学学报，第24卷第6期 2001 * |
| 高尿酸血症动物模型初探 唐灿等，中药新药与临场药理，第11卷第5期 2000 * |
| 高尿酸血症动物模型初探 唐灿等，中药新药与临场药理，第11卷第5期 2000;高尿酸血症动物模型的研究进展 陈光亮等，中国药理学通报，第20卷第4期 2004;高尿酸血症动物模型研究进展 王勇等，中华实用中西医杂志，第3卷第16期 2003;小鼠高尿酸血症复合模型初探 张浩军等，北京中医药大学学报，第24卷第6期 2001 * |
| 高尿酸血症动物模型的研究进展 陈光亮等，中国药理学通报，第20卷第4期 2004 * |
| 高尿酸血症动物模型研究进展 王勇等，中华实用中西医杂志，第3卷第16期 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1698907A (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1314454C (en) | Duplication method of chmice acute hyperuricemia model | |
| CN1698906A (en) | Duplication method of rat acute or persistent hyperuricemia model | |
| US20070042995A1 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| CN1217002C (en) | Method for producing aclenosylmethionine by enzyme catalysis | |
| JP2002065288A (en) | Method for selectively producing triprenyl phenol compound and utilization of the same compound as medicine | |
| CN1422252A (en) | Chemokine receptor antagonists | |
| CN1398861A (en) | Prepn and application in preparing medicine of Fraxinus general coumarin | |
| US7037904B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for suppressing side-effect of radiotherapy and chemotherapy | |
| CN1550545A (en) | Method of producing lactic bacteria and killed lactic bacterial cells belonging to the enterococcus | |
| CN1718183A (en) | Neo-garcinolic acid prepn. for injection use, prepn. method and use thereof | |
| US20100256230A1 (en) | 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof | |
| CN1194690C (en) | Composition for treating bronchial asthma and allergic rhinitis | |
| CN1184965C (en) | Remedies for arthrosis deformans | |
| CN103833564B (en) | L-Orn glutamic acid double salt and its preparation method and application | |
| CN1030133C (en) | 1,6-fructose diphosphate sodium salt oral liquid | |
| EP0794193B1 (en) | Substance mk7634, process for production thereof, and anthelminthic containing said substance | |
| CN1732005A (en) | Use of istradefylline (kw-6002) for the treatment of behavioral disorders | |
| CN1919258A (en) | Application of schisandra chinensis in the preparation of medicine for preventing and reducing toxic and side effect of antitumor agent | |
| JP3683003B2 (en) | Anti-tumor substance epolactaene | |
| CN116919975A (en) | Osteoclast differentiation inhibitor and preparation method and application thereof | |
| CA2205420C (en) | Substance mk7634, process for production thereof, and anthelminthic containing said substance | |
| CN117530949A (en) | New application of FN-1501 in preparing medicine for treating and preventing autoimmune disease | |
| CN115650944A (en) | Compounds capable of reducing uric acid | |
| US20070160527A1 (en) | Use of n-acetyl-d-aminoglycosamine in treatment of local lesions or systematic symptoms related to autoimmune reactions | |
| CN1473569A (en) | Composite preparation of sodium para-aminosallicylate and trimethoprim |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070509 Termination date: 20100606 |